Psilocybin Tolerance Calculator
Calculate precise dosage recommendations based on your tolerance level, weight, mushroom type, and previous usage patterns for a safe psychedelic experience.
Dosage Recommendations
How Tolerance Works
Psilocybin tolerance develops rapidly after use and affects how your body responds to subsequent doses. Tolerance to psilocybin can develop within hours of consumption and typically peaks around 24-72 hours after use.
Tolerance Timeline
0-1 Days
Peak tolerance – may require 2-4x normal dose for similar effects. Not recommended due to diminishing returns and increased risk.
2-3 Days
High tolerance – approximately 1.5-2x normal dose needed. Still not optimal timing for redosing.
4-7 Days
Moderate tolerance – may need 1.2-1.5x normal dose. Some tolerance effects still present.
7-14 Days
Minimal tolerance – close to baseline sensitivity. Recommended minimum wait time between sessions.
Factors Affecting Dosage
Body Weight
Heavier individuals generally require higher doses, though the relationship isn’t perfectly linear. Metabolism also plays a role.
Mushroom Potency
Psilocybin content varies significantly between species and even individual mushrooms. Proper identification is crucial.
Individual Sensitivity
Natural sensitivity varies greatly between individuals. Some people are naturally more or less sensitive to psychedelics.
Set and Setting
Your mental state and physical environment significantly influence the intensity and quality of the experience.
Stomach Contents
Taking mushrooms on an empty stomach typically results in faster onset and stronger effects compared to a full stomach.
Medication Interactions
SSRIs, MAOIs, and other medications can interact with psilocybin, potentially reducing effects or causing dangerous interactions.
Dosage Categories Explained
Microdose (0.1-0.5g dried): Sub-perceptual doses that may enhance mood, creativity, and focus without producing noticeable psychedelic effects. Typically taken every 3-4 days.
Light Dose (0.5-2g dried): Produces mild euphoria, slight visual enhancements, and increased emotional sensitivity. Good for beginners or those seeking a gentle experience.
Moderate Dose (2-3.5g dried): Clear psychedelic effects including visual distortions, altered perception of time, and enhanced introspection. Most common recreational dose.
Strong Dose (3.5-5g dried): Intense visual hallucinations, profound alterations in consciousness, and potential ego dissolution. Requires experience and careful preparation.
Safety Guidelines
- Always test a small amount first if using a new batch or source
- Have a sober trip sitter present, especially for higher doses
- Create a safe, comfortable environment free from obligations
- Stay hydrated but avoid excessive water consumption
- Avoid mixing with alcohol or other substances
- Don’t drive or operate machinery for at least 8-12 hours
- If you feel overwhelmed, remember the effects are temporary
- Consider having benzodiazepines available as a trip killer if needed
When NOT to Use
- History of psychosis, schizophrenia, or bipolar disorder
- Currently taking antidepressants or other psychiatric medications
- In an unstable mental or emotional state
- Pregnant or breastfeeding
- Under 21 years of age (brain still developing)
- In an unfamiliar or unsafe environment
- When you have important responsibilities or commitments
References
Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology, 22(6), 603-620.
Studerus, E., Gamma, A., & Vollenweider, F. X. (2010). Psychometric evaluation of the altered states of consciousness rating scale (OAV). PloS one, 5(8), e12412.
Fantegrossi, W. E., Murnane, K. S., & Reissig, C. J. (2008). The behavioral pharmacology of hallucinogens. Biochemical pharmacology, 75(1), 17-33.
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms. Journal of Psychopharmacology, 30(12), 1279-1295.
Bogenschutz, M. P., & Johnson, M. W. (2016). Classic hallucinogens in the treatment of addictions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 64, 250-258.
Nichols, D. E. (2016). Psychedelics. Pharmacological reviews, 68(2), 264-355.